PolyPid Ltd. announced on December 11, 2024, a new research and development collaboration with ImmunoGenesis, Inc., a clinical-stage biotechnology company. The collaboration focuses on developing novel formulations for solid tumors.
This initiative will leverage PolyPid’s proprietary PLEX Technology with ImmunoGenesis’ STimulator of INterferon Genes (STING) agonist drug candidate. The goal is to enhance cancer immunotherapy by addressing the rapid clearance of potent STING agonists.
The PLEX technology aims to enable prolonged intratumoral drug delivery, thereby increasing the exposure time within the tumor microenvironment for effective anti-tumor activity. This collaboration expands PolyPid's platform application into immuno-oncology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.